{"transactions":[{"id":741321,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:36:42.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock (\"Company Option\") that was outstanding and unexercised immediately prior to the effective time of the Merger (the \"Effective Time\") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a 3 year period: 1/36th vests on November 1, 2025, after which 1/36th of the total shares vest monthly, subject to reporting person's continued service through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":12.05,"expiration_date":"2035-09-30","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001899935-26-000007","document":"form4-06112026_080638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000189993526000007/form4-06112026_080638.xml","form_type":"4"}},{"id":805131,"issuer":{"id":6339,"kind":"organization","name":"Alpha Cognition Inc.","symbol":"ACOG"},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Share Options","published_at":"2026-04-17T19:56:53.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":6991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest one year from date of grant."}],"balance_after":6991,"derivative":{"exercise_price":6.65,"expiration_date":"2036-04-16","underlying":"Common Shares","underlying_shares":6991},"source":{"system":"sec-edgar","filing":"0000912282-26-000624","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655923/000091228226000624/form4.xml","form_type":"4"}},{"id":805130,"issuer":{"id":6339,"kind":"organization","name":"Alpha Cognition Inc.","symbol":"ACOG"},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-04-17T19:56:53.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":5489,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units that vest one year from date of grant."}],"balance_after":5489,"source":{"system":"sec-edgar","filing":"0000912282-26-000624","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655923/000091228226000624/form4.xml","form_type":"4"}},{"id":887666,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-23T21:39:45.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":4475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4475},"source":{"system":"sec-edgar","filing":"0001899935-26-000005","document":"wk-form4_1771882782.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000189993526000005/wk-form4_1771882782.xml","form_type":"4"}},{"id":887665,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:39:45.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":3258,"price":51.27,"value":167037.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.98 to $51.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001899935-26-000005","document":"wk-form4_1771882782.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000189993526000005/wk-form4_1771882782.xml","form_type":"4"}},{"id":887664,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:39:45.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":1217,"price":50.31,"value":61227.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.71. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":3258,"source":{"system":"sec-edgar","filing":"0001899935-26-000005","document":"wk-form4_1771882782.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000189993526000005/wk-form4_1771882782.xml","form_type":"4"}},{"id":887663,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:39:45.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":4475,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4475,"source":{"system":"sec-edgar","filing":"0001899935-26-000005","document":"wk-form4_1771882782.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000189993526000005/wk-form4_1771882782.xml","form_type":"4"}},{"id":890349,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-02-20T21:43:00.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":4977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option vests on February 18, 2027."}],"balance_after":4977,"derivative":{"exercise_price":50.2,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":4977},"source":{"system":"sec-edgar","filing":"0001899935-26-000003","document":"wk-form4_1771623777.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000189993526000003/wk-form4_1771623777.xml","form_type":"4"}},{"id":890348,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-20T21:43:00.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":2989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027."}],"balance_after":2989,"derivative":{"underlying":"Common Stock","underlying_shares":2989},"source":{"system":"sec-edgar","filing":"0001899935-26-000003","document":"wk-form4_1771623777.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000189993526000003/wk-form4_1771623777.xml","form_type":"4"}},{"id":1026616,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-02T22:28:21.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 3-year period: 1/36th vests on November 1, 2025, after which 1/36th of the total shares vest monthly, subject to reporting person's continued service through each vesting date."}],"balance_after":45000,"derivative":{"exercise_price":12.05,"expiration_date":"2035-09-30","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001899935-25-000005","document":"form4-10022025_101017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348911/000189993525000005/form4-10022025_101017.xml","form_type":"4"}},{"id":1063630,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-18T20:31:18.000Z","date":"2025-08-14","kind":"sale","planned":true,"acquired":false,"shares":5369,"price":42.25,"value":226840.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.88 to $42.52. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-25-040668","document":"wk-form4_1755549074.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000162828025040668/wk-form4_1755549074.xml","form_type":"4"}},{"id":1249162,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-02-24T22:41:09.000Z","date":"2025-02-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5369},"source":{"system":"sec-edgar","filing":"0001628280-25-007459","document":"wk-form4_1740436862.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000162828025007459/wk-form4_1740436862.xml","form_type":"4"}},{"id":1249161,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-24T22:41:09.000Z","date":"2025-02-22","kind":"grant","planned":false,"acquired":true,"shares":5369,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5369,"source":{"system":"sec-edgar","filing":"0001628280-25-007459","document":"wk-form4_1740436862.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000162828025007459/wk-form4_1740436862.xml","form_type":"4"}},{"id":1252457,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-02-21T21:48:19.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":4475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026."}],"balance_after":4475,"derivative":{"underlying":"Common Stock","underlying_shares":4475},"source":{"system":"sec-edgar","filing":"0001628280-25-007182","document":"wk-form4_1740174492.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000162828025007182/wk-form4_1740174492.xml","form_type":"4"}},{"id":1252456,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-02-21T21:48:19.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":7296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on February 19, 2026."}],"balance_after":7296,"derivative":{"exercise_price":33.52,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":7296},"source":{"system":"sec-edgar","filing":"0001628280-25-007182","document":"wk-form4_1740174492.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000162828025007182/wk-form4_1740174492.xml","form_type":"4"}},{"id":1618891,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-02-26T22:01:47.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":5369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025."}],"balance_after":5369,"derivative":{"underlying":"Common Stock","underlying_shares":5369},"source":{"system":"sec-edgar","filing":"0001104659-24-027575","document":"tm247055-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924027575/tm247055-9_4seq1.xml","form_type":"4"}},{"id":1618890,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-02-26T22:01:47.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":8252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on February 22, 2025."}],"balance_after":8252,"derivative":{"exercise_price":27.94,"expiration_date":"2034-02-22","underlying":"Common Stock","underlying_shares":8252},"source":{"system":"sec-edgar","filing":"0001104659-24-027575","document":"tm247055-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924027575/tm247055-9_4seq1.xml","form_type":"4"}},{"id":1800552,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-08-21T21:10:08.000Z","date":"2023-08-17","kind":"grant","planned":false,"acquired":true,"shares":24153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal annual installments beginning on August 17, 2024."}],"balance_after":24153,"derivative":{"exercise_price":30.22,"expiration_date":"2033-08-17","underlying":"Common Stock","underlying_shares":24153},"source":{"system":"sec-edgar","filing":"0001104659-23-093982","document":"tm2324240-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923093982/tm2324240-2_4seq1.xml","form_type":"4"}},{"id":1915472,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2023-04-21T17:08:33.000Z","date":"2023-04-21","kind":"sale","planned":false,"acquired":false,"shares":9100,"price":1.21,"value":11011.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover taxes upon the vesting of restricted stock units on April 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.23. The reporting person undertakes to provide to 9 Meters Biopharma, Inc., any security holder of 9 Meters Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4."}],"balance_after":41077,"source":{"system":"sec-edgar","filing":"0001551986-23-000026","document":"wf-form4_168211130140021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198623000026/wf-form4_168211130140021.xml","form_type":"4"}},{"id":1935548,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-29T16:09:52.000Z","date":"2023-03-27","kind":"grant","planned":false,"acquired":true,"shares":50177,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted pursuant to the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan.  Each RSU represents a contingent right to receive one share of common stock upon the vesting date.  The RSUs vest as follows:  25,089 shares vest on April 15, 2023 and 25,088 shares vest on December 31, 2023. The vesting of the December 31, 2023 RSUs will accelerate upon a change in control prior to December 31, 2023."}],"balance_after":50177,"source":{"system":"sec-edgar","filing":"0001578563-23-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000157856323000009/primary_doc.xml","form_type":"4"}},{"id":2433420,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":39183,"kind":"person","name":"Sensenig Bethany","position":1,"cik":"0001899935","reported_name":"Sensenig Bethany","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-18T19:24:35.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":1300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of these shares shall be deemed vested and exercisable on January 18, 2023 with the remainder vesting in equal monthly installments over the next 36 months, such that the option shall be fully vested on January 18, 2026, subject to the executive's continued service with the Company through each applicable vesting date."}],"balance_after":1300000,"derivative":{"exercise_price":0.8449,"expiration_date":"2032-01-18","underlying":"Common stock","underlying_shares":1300000},"source":{"system":"sec-edgar","filing":"0001551986-22-000011","document":"wf-form4_164255186024173.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198622000011/wf-form4_164255186024173.xml","form_type":"4"}}]}